Kancure, LLC is a start-up biotechnology company aiming at the development of an anti-cancer drug treatment for Chronic Myeloid Leukemia, created as part of a mock assignment in the Entrepreneurial Biotechnology course.

10. Competition Not effective in T315I mutation. Not effective against T3151 mutation. Not effective against T315I mutation. Not effective in Blast crisis. Not Effective in Blast crisis Not effective in Blast crisis 29 million in 2008 142 millions in 2008 1800 millions in 2008 Novartis Bristols-myers Squibs Novartis Tasigna Sprycel Gleevec

12. Marketing Channels Marketing Channels http:// www.Kancure.com

14. LeukX Competitor & Pricing LeukX Price: $30 per 100 mg “ Oncology is the top of the bill when it comes to new products in development..” USA Today – May 2008 CML Drug market was more than $7 billion globally in 2008 Competitor Sales Volume Gleevec 1,800 Million Sprycel 142 Million Tasigna 29 Million

17. Sources of Capital

18. Projected Income Statement

19. Profit Projection

21. Break Even Analysis

22. VC Funding Total: $14,000,000 $10M $ 7.37 52.63% 1,900,000 VC Phase II $4 M $ 2.963 74.07% 1,350,000 VC Phase I $540,000 $ .54 100% 1,000,000 Initial Valuation Price/Share %Company # Of Shares Round

23. Thank You